You just read:

Isis Initates Phase 2/3 Study Of ISIS-TTR Rx And Earns $7.5 Million Milestone Payment From GlaxoSmithKline

News provided by

Isis Pharmaceuticals, Inc.

Feb 19, 2013, 07:00 EST